multicenter clinical trial of atovaquone (atq) for salvage treatment and suppression of toxoplasmic encephalitis (te). the atq/te study group.

NLM AIDSLINE Multicenter clinical trial of atovaquone (ATQ) for salvage treatment and suppression of toxoplasmic encephalitis (TE). The ATQ/TE Study Group. Torres R; Weinberg W; Stansell J; Leoung G; Kovacs J; Rogers M
November 30, 1993

Int Conf AIDS. 1993 Jun 6-11;9(1):377 (abstract no. PO-B10-1453). Unique OBJECTIVE: To assess the efficacy, safety and tolerance of ATQ for salvage therapy of TE. METHODS: 93 AIDS patients with presumptive or biopsy-proven TE were treated with 750mg ATQ qid as salvage therapy in an open, noncomparative clinical trial. Clinical and neuroradiological (CT or MRI) assessments were made to assess response. Patients were followed until death. The relationship between ATQ plasma conc. and survival was tested Kaplan-Meier Product-Limit Method). RESULTS: TABULAR DATA, SEE ABSTRACT VOLUME. After six weeks of therapy, 88%, 63% and 54% were clinically stable or improved, and 68%, 50% and 38% were radiologically stable or improved, with ATQ plasma conc. of > 13 micrograms/ml, 7-13 micrograms/ml and < 7 micrograms/ml, respectively. Clinical improvement correlated with reduction in lesion size. ATQ was generally well-tolerated. Of note, there was only 1 case of Pneumocystis carinii pneumonia in 64 patients without PCP prophylaxis (mean time on ATQ = 124 days). CONCLUSION: There is an ATQ plasma conc.-response and survival relationship. Salvage treatment of TE patients with ATQ is associated with clinical and radiological improvement and prolonged survival. Antiprotozoal Agents/THERAPEUTIC USE AIDS-Related Opportunistic Infections/DRUG THERAPY Encephalitis/DRUG THERAPY Naphthoquinones/THERAPEUTIC USE *Toxoplasmosis, Cerebral/DRUG THERAPY

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 OHIO: Phila Health Department HIV Testing Well-Received CONNECTICUT: City's Circle Care Center is a Model for HIV Prevention UNITED STATES: New Compound Excels at Killing Persistent and Drug-Resistant Tuberculosis INDIA: India Faces TB Drug Shortage, Warns International Medical Org ALASKA: After Topping List for Chlamydia Rates, Alaska Seeing Some Improvement Tanzania: Police Abuse, Torture, Impede HIV Services Growing HIV/AIDS awareness in Indonesia's Papua region South Africa: Catastrophe as Eastern Cape drug stock-outs continue Community-led programmes critical to progress on AIDS in Sri Lanka One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs FLORIDA: Groups Offering Free HIV Testing Study shows PreP works for IDU Civil confinement trial for NY sex offender begins CLAAD Urges FDA To End Abstinence-Only Stance On Addiction Treatment Study Shows Pill Prevents H.I.V. Among Drug Addicts Study: AIDS Drug Cuts Infections Among Drug Users Thailand-US Study Concludes Effectiveness of Daily HIV Medication Spanish austerity cuts put lives at risk, study finds New PrEP Trial Results Among Injecting Drug Users Underscore That PrEP Works When Taken Consistently AIDS drugs halve HIV risk for intravenous drug users in study
Information in this article was accurate in November 30, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.